SEZABY CIV

Must be experienced in managing serious cardiorespiratory adverse reactions (including airway management). Dependence and withdrawal reactions. Avoid abrupt cessation if used for a longer duration than recommended; withdraw gradually. Not approved for use in adolescents or adults; unapproved use exposes them to risks of abuse, misuse, and addiction. Monitor for respiratory depression or insufficiency. Discontinue at the 1^st sign of a rash, unless not drug related. If serious dermatologic reactions (eg, Stevens-Johnson syndrome [SJS] or toxic epidermal necrolysis [TEN]) signs/symptoms occur, do not resume and consider alternative therapy. Evaluate immediately if signs/symptoms of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or hypersensitivity reactions develop; discontinue if alternative etiology cannot be established. Avoid in those who are at significant risk of developing torsade de pointes (eg, congenital long QT syndrome, uncontrolled or significant cardiac disease, recent MI, HF, unstable angina, bradyarrhythmias, AV block, aortic stenosis, uncontrolled hypothyroidism); if unavoidable, obtain ECGs during treatment, monitor serum electrolytes and correct abnormalities. Avoid perivascular extravasation or intra-arterial injection. Discontinue if infusion site reactions occur. Embryo-fetal toxicity. Neonates exposed through breast milk; monitor.